A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

NCT05446129 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Company decision

Conditions

Colorectal Cancer

Interventions

DRUG: Ezabenlimab
DRUG: BI 765063
DRUG: Pembrolizumab

Sponsor

Boehringer Ingelheim